Here is our Top Docs 2025 profile on Jeffrey Zonder, M.D., who is part of the Karmanos Cancer Institute’s Multiple Myeloma and Amyloidosis Multidisciplinary Team.

Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...

Multiple crashes in Henry County and the city of Martinsville claimed two lives and resulted in at least one arrest over the weekend. At approximately 7:20 p.m. Saturday, a two-vehicle crash in the ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple ...

At a median follow-up of 39.4 months, results from the second interim analysis showed a sustained and significant OS benefit with BVd compared to DVd.

As September concludes, the landscape of hematologic oncology continues to evolve, spanning the full spectrum of blood cancer ...

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...

At a live event in White Plains, New York, Adriana Rossi, MD, assistant professor of medicine and director of CAR T and the Stem Cell Transplant Clinical Service at the Center of Excellence for ...

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

Although multiple myeloma is often considered incurable, the development of highly effective new therapies is creating a real possibility of a cure for some patients. Current 4-drug upfront regimens, ...

Background aims: Chimeric antigen receptor (CAR) T-cell therapy shows remarkable efficacy against relapsed/refractory multiple myeloma (R/R MM). Nutritional status, assessed by objective indices like ...